Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.

So go here now to read my new report The Big AI Die-Up… while you still can.

Anil P. Ranganath net worth and biography

Anil Ranganath Biography and Net Worth

Insider of TransMedics Group

Anil Ranganath joins TransMedics with over 15 years of experience in the life sciences and biotechnology tools industries. Prior to joining TransMedics, Mr. Ranganath served multiple roles of increasing scope and responsibility at Waters Corporation. Most recently, Mr. Ranganath served as Vice President, Deputy General Counsel for Waters, managing legal affairs, and serving as a trusted advisor on Waters’ strategic, tactical, and operational plans. He began his legal career as an Associate at Brown Rudnick LLP, representing life sciences and biotechnology companies on corporate and intellectual property matters. Mr. Ranganath holds a Juris Doctorate from Suffolk University Law School and a Bachelor’s degree in Computer Science from Worcester Polytechnic Institute.

What is Anil P. Ranganath's net worth?: The estimated net worth of Anil P. Ranganath is at least $1.47 million as of August 7th, 2024. Mr. Ranganath owns 8,893 shares of TransMedics Group stock worth more than $1,467,345 as of September 21st. This net worth estimate does not reflect any other assets that Mr. Ranganath may own. Learn More about Anil P. Ranganath's net worth.
How do I contact Anil P. Ranganath?: The corporate mailing address for Mr. Ranganath and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Anil P. Ranganath's contact information.
Has Anil P. Ranganath been buying or selling shares of TransMedics Group?: During the past quarter, Anil P. Ranganath has sold $652,785.80 in shares of TransMedics Group stock. Most recently, Anil P. Ranganath sold 4,289 shares of the business's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a transaction totalling $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares of the company's stock, valued at $1,353,514.60. Learn More on Anil P. Ranganath's trading history.
Who are TransMedics Group's active insiders?: TransMedics Group's insider roster includes John Carey (VP), Nicholas Corcoran (Insider), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), Miriam Provost (VP), and Anil Ranganath (Insider). Learn More on TransMedics Group's active insiders.
Are insiders buying or selling shares of TransMedics Group?: In the last year, insiders at the sold shares 44 times. They sold a total of 479,522 shares worth more than $52,971,703.08. The most recent insider tranaction occured on September, 16th when CEO Waleed H Hassanein sold 8,625 shares worth more than $1,323,247.50. Insiders at TransMedics Group own 7.0% of the company. Learn More about insider trades at TransMedics Group.
Information on this page was last updated on 9/16/2024.

Anil P. Ranganath Insider Trading History at TransMedics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/7/2024	Sell	4,289	$152.20	$652,785.80	8,893
6/5/2024	Sell	703	$135.21	$95,052.63	8,809

Anil P. Ranganath Buying and Selling Activity at TransMedics Group

TransMedics Group Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Today's Range

Now: $165.00

$161.87

$169.29

50 Day Range

MA: $155.65

$135.68

$176.11

2 Week Range

Now: $165.00

$36.42

$177.37

Volume

1,182,660 shs

Average Volume

777,688 shs

Market Capitalization

$5.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

The $15 "Insider Secret" That Could Save Your Retirement

From Behind the Markets | Ad

What if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.

Click here to discover the name and ticker of this "$15 billionaire-backed retirement stock" >>>